产品详情
简单介绍：
Anti-CARD15抗体产品质量稳定，实验效果明显，货期快，价格优惠，欢迎垂询订购！我公司长期供应**组化抗体、WB抗体、**组化试剂盒和抗体试验所需全部相关试剂、荧光标记抗体、单克隆抗体、多克隆抗体、各种标记的二抗IgG/IgM/IgD/IgA等科研实验抗体。Anti-CARD15抗体用于**组化实验,WB实验,相应的标记抗体有HRP标记抗体,FITC标记,BIO等。
详情介绍：
Rabbit Anti-CARD15
Cat. Number:
Anti-CARD15抗体KL-7084R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Defects in NOD2 are the cause of sarcoidosis early-onset (EOS) . EOS is a form of sarcoidosis manifesting in children younger than 4 years of age. Sarcoidosis is an idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs Anti-CARD15抗体may be involved. Early-onset sarcoidosis is quite rare and has a distinct triad of skin, joint and eye disorders, without apparent pulmonary involvement. Compared with an asymptomatic and sometimes naturally disappearing course of the disease in older children, early-onset sarcoidosis is progressive and in many cases causes severe complications, such as blindness, joint destruction and visceral involvement.
Also known as:
ACUG; Arthrocutaneouveal granulomatosis; BLAU; CARD15; Caspase recruitment domain protein 15; Caspase recruitmentAnti-CARD15抗体 domain-containing protein 15; CD; IBD1; Inflammatory bowel disease protein 1; LRR containing protein; LRR-containing protein; Nod2; NOD2 protein; NOD2_HUMAN; NOD2B; nucleotide binding oligomerization domain 2; nucleotide-binding oligomerization domain 2; Nucleotide-binding oligomerization domain-containing protein 2; PSORAS1.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, .
●
Immunogen: KLH conjugated synthetic peptide derived from human CARD15.
●
Predicted Molecular Weight:Anti-CARD15抗体 114kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:50-500 IF=1:100-500
Not yet tested in other applications.
Optimal working dilutionsAnti-CARD15抗体 must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutionsAnti-CARD15抗体 must be determined by the end user.
kl043Mu01 维甲酸X受体α(RXRα)多克隆抗体 Polyclonal Antibody to Retinoid X Receptor Alpha (RXRa)
kl043Mu02 维甲酸X受体α(RXRα)多克隆抗体 Polyclonal Antibody to Retinoid X Receptor Alpha (RXRa)
kl044Mu01 肝X受体α(LXRα)多克隆抗体 Polyclonal Antibody to Liver X Receptor Alpha (LXRa)
kl044Mu02 肝X受体α(LXRα)多克隆抗体 Polyclonal Antibody to Liver X Receptor Alpha (LXRa)
kl045Mu02 存活素(Surv)多克隆抗体 Polyclonal Antibody to Survivin (Surv)
kl046Mu01 S100钙结合蛋白A10(S100A10)多克隆抗体 Polyclonal Antibody to S100 Calcium Binding Protein A10 (S100A10)
kl046Mu02 S100钙结合蛋白A10(S100A10)多克隆抗体 Polyclonal Antibody to S100 Calcium Binding Protein A10 (S100A10)
kl047Mu02 Ki-67蛋白(Ki67P)多克隆抗体 Polyclonal Antibody to Ki-67 Protein (Ki67P)
kl056Mu02 基质金属蛋白酶14(MMP14)多克隆抗体 Polyclonal Antibody to Matrix Metalloproteinase 14 (MMP14)
kl058Mu01 白介素20(IL20)多克隆抗体 Polyclonal Antibody to Interleukin 20 (IL20)
kl058Mu02 白介素20(IL20)多克隆抗体 Polyclonal Antibody to Interleukin 20 (IL20)
kl058Ra01 白介素20(IL20)多克隆抗体 Polyclonal Antibody to Interleukin 20 (IL20)
kl059Hu01 周期素依赖性激酶6(CDK6)多克隆抗体 Polyclonal Antibody to Cyclin Dependent Kinase 6 (CDK6)
kl064Mu02 白介素24(IL24)多克隆抗体 Polyclonal Antibody to Interleukin 24 (IL24)
kl068Mu01 VEGF共调节趋化因子1(VCC1)多克隆抗体 Polyclonal Antibody to VEGF Co Regulated Chemokine 1 (VCC1)
kl068Mu02 VEGF共调节趋化因子1(VCC1)多克隆抗体 Polyclonal Antibody to VEGF Co Regulated Chemokine 1 (VCC1)
kl068Ra01 VEGF共调节趋化因子1(VCC1)多克隆抗体 Polyclonal Antibody to VEGF Co Regulated Chemokine 1 (VCC1)
kl071Mu01 干扰素诱导T-细胞α亚族趋化剂(ITαC)多克隆抗体 Polyclonal Antibody to Interferon Inducible T-Cell Alpha Chemoattractant (ITaC)
kl071Mu02 干扰素诱导T-细胞α亚族趋化剂(ITαC)多克隆抗体 Polyclonal Antibody to Interferon Inducible T-Cell Alpha Chemoattractant (ITaC)
kl075Mu02 单核细胞趋化蛋白5(MCP5)多克隆抗体 Polyclonal Antibody to Monocyte Chemotactic Protein 5 (MCP5)
